Former Novo Nordisk North America chief joins board of US biotech company. Click Therapeutics has appointed Doug Langa, former Novo Nordisk North America executive, to its board of directors. 4 August 2026at 08:55 Try MedWatch for 14 days - and get access to all content. * Continues as a recurring subscription and is billed annually. Can be terminated after 5 months of subscription with 1 month's notice at the end of a month. Minimum price is up to €539.58 excl. VAT corresponding to 7 months of subscription. Right of withdrawal under the Consumer Contracts Act. Read more here. ** Continues as a recurring subscription for 3 months at a time. Minimum price €286.00 excl. VAT. Can be terminated with 1 month's notice at the end of a 3-month period. Right of withdrawal under the Consumer Contracts Act. Read more here.

Ross Muken to become CEO as SOPHiA GENETICS confirms succession plan ahead of Annual meeting. June 10, 2026 Ross Muken SOPHiA GENETICS (Nasdaq: SOPH) has confirmed a previously announced leadership transition that will see President Ross Muken become chief executive officer on July 1, 2026, as the company positions itself for its next phase of growth in AI-driven precision medicine. The leadership changes, which will be presented to shareholders at the company's Annual General Meeting on June 18, follow a multi-year succession planning process overseen by the board of directors. Under the proposed structure, co-founder and current Chief Executive Officer Dr. Jurgi Camblong will transition to Executive Chairman, while current Chairman Troy Cox will remain on the board as a non-executive director. The transition comes at a pivotal stage for SOPHiA GENETICS as healthcare organizations increasingly adopt artificial intelligence and data-driven technologies to improve diagnostics, treatment selection and patient outcomes. The company has built a global network of nearly 1,000 healthcare institutions across more than 75 countries and has analyzed more than 2 million genomic profiles through its SOPHiA DDM platform. Muken, who joined the company in 2021 as chief financial officer, has steadily expanded his responsibilities over the past five years. He was appointed CFO and chief operating officer in 2023 before becoming president in late 2024. Subject to shareholder approval, he will also join the board of directors when he assumes the CEO role. The board cited Muken's combination of operational, financial and strategic experience, as well as his deep familiarity with the business, as key factors in its succession decision. "I am deeply honored by Jurgi and the Board's confidence in me to lead SOPHiA GENETICS at this important moment," Muken said. "Jurgi has built a truly exceptional company with a clear mission, a differentiated platform, and a passionate team dedicated to improving patient outcomes. I am excited to build on that foundation, accelerate our commercial momentum, and continue delivering value for patients, customers, and shareholders alike." Before joining SOPHiA GENETICS, Muken served as CFO and COO of Click Therapeutics and held senior roles at Evercore/ISI Group, Deutsche Bank Securities and Thomas Weisel Partners. His background spans life sciences, healthcare technology, medical devices and pharmaceutical services. The transition also marks a new chapter for Camblong, who co-founded SOPHiA GENETICS in 2011 and has led the company since its inception. Under his leadership, the business evolved from a Swiss startup into a publicly traded healthcare technology company focused on applying artificial intelligence to genomic and multimodal healthcare data. If elected chairman, Camblong will remain a full-time executive focused on technology innovation and long-term strategy while working closely with Muken on the company's commercial and operational growth initiatives. "This transition marks an exciting new chapter, one where I can further contribute strategically at the Board level as we continue to advance our vision of democratizing data-driven medicine at scale," Camblong said. "I look forward to continuing working closely with Ross as he leads the company into its next phase of growth." Cox, who joined the board in 2019 and became chairman in 2020, helped guide the company through several significant milestones, including its Nasdaq initial public offering in 2021 and its subsequent international expansion. Prior to SOPHiA GENETICS, he served as chief executive officer of Foundation Medicine and led the company through its acquisition by Roche. "Succession is one of the most important responsibilities of any Board, and I am proud of the disciplined, multi-year process that has led to today's announcement," Cox said. "Jurgi's founder vision belongs at the Chair, and Ross's strategic, commercial, and operational track record make him the right CEO to scale the business through its next phase of growth." Alongside the executive transition, SOPHiA GENETICS plans to strengthen its governance structure. The company intends to establish a Lead Independent Director position, rotating annually among the chairs of its independent board committees, and will hold executive sessions exclusively for independent directors at each board meeting. The company noted that these measures, combined with an independent board majority and fully independent committees, are designed to support strong oversight as the business continues to scale. The leadership changes underscore SOPHiA GENETICS' focus on balancing continuity and innovation as artificial intelligence becomes increasingly central to healthcare decision-making. With Camblong remaining closely involved in strategy and technology development and Muken taking responsibility for execution and growth, the company is positioning itself to capitalize on growing demand for AI-powered precision medicine solutions across healthcare systems, laboratories and biopharmaceutical organizations worldwide.